• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Quarterly canakinumab administration associated with significantly reduced risk for gout attacks

byCaitlyn HuiandDeepti Shroff Karhade
September 18, 2018
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Use of canakinumab was associated with reduced risk for gout attacks.

2. Canakinumab administration did not result in changes to serum uric acid levels.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Gout is the most common inflammatory arthritis in adults, and its prevalence has increased substantially over the past several decades. In terms of therapy, most drugs that inhibit interleukin-1B have been shown to shorten gout attacks, but it is unclear whether they stop these attacks from occurring. The authors of this study examined the relationship of one of the common therapies for gout, canakinumab, and the lowering of serum uric acid levels (SUA) as well as frequency of gout attacks. Generally, they observed that quarterly canakinumab administration was associated with significantly reduced risk for gout attacks. However, they noted that the high cost of this drug could pose issues. The main limitation of this study was the fact that incidence reports of gout attacks did not require a physician’s diagnosis, meaning there was possible misclassification of gout attacks in analyses.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomized study

RELATED REPORTS

Sodium-glucose cotransporter-2 inhibitors may decrease incidence of recurrent gout flares

#VisualAbstract: SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout

SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout

In-Depth [randomized controlled trial]: The authors conducted a secondary analysis of a randomized controlled trial to assess the relationship among canakinumab, a monoclonal antibody targeting IL-1B, SUA levels, and gout attack incidence among 10 059 participants. The study setting included patients from 39 countries and resulted in random allocation of the drug versus placebo, administered every 3 months. The overall incidence rate of gout among the intervention group was 0.38 attacks per 100 person-years, compared to 0.80 attacks per 100-person years in the placebo group. Canakinumab did not affect the overall SUA levels over time.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: canakinumabgout
Previous Post

Tailoring fecal immunochemical tests positivity thresholds by age and sex may help to optimize colorectal cancer screening

Next Post

Symptoms of burnout and career regret prevalent among U.S. resident trainees

RelatedReports

Quick Take: Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout
Chronic Disease

Sodium-glucose cotransporter-2 inhibitors may decrease incidence of recurrent gout flares

October 11, 2023
#VisualAbstract: SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout
StudyGraphics

#VisualAbstract: SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout

August 9, 2023
Quick Take: Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout
Chronic Disease

SGLT2 inhibitors reduce recurrent flares and hospitalizations in patients with gout

August 4, 2023
#VisualAbstract: Changes in prescription drug and health care use over 9 years after the large drug price increase for colchicine
StudyGraphics

#VisualAbstract: Changes in prescription drug and health care use over 9 years after the large drug price increase for colchicine

May 31, 2023
Next Post
Earlier puberty associated with increased risk of depression in girls

Symptoms of burnout and career regret prevalent among U.S. resident trainees

Palliative care consultation linked to lower deaths by failed code resuscitation

Palliative care consultation linked to lower deaths by failed code resuscitation

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

PET imaging of tau may help distinguish Alzheimer Disease from other neurodegenerative disorders

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
  • #VisualAbstract: Lactated Ringer’s Solution Does Not Improve Outcomes Relative to Normal Saline
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [July 2nd, 2025]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.